P028 | WORSENING OF MIGRAINE AFTER DISCONTINUATION OF ANTI-CGRP MONOCLONAL ANTIBODIES: PATIENTS WITHOUT RECURRENCE FOR AT LEAST 6 MONTHS
Confinia Cephalalgica · 03.11.2026 · 36 (s1)
DOI: 10.4081/cc.2026.15984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Monoclonal antibodies targeting CGRP or its receptor are widely used for migraine prevention. However, the optimal timing of treatment discontinuation and the subsequent clinical course remain unclear. This study evaluated the frequency of worsening after discontinuation and associated factors among responders, defined as patients who achieved a ≥50% reduction in monthly headache days (MHD), and who discontinued treatment after shared decision-making.
Methods
We conducted a retrospective analysis at two specialized-headache clinics. Patients with migraine were included if they had received anti-CGRP monoclonal antibodies for at least 3 months, achieved a ≥50% reduction in MHD, discontinued treatment at the patient’s request and in agreement with the physician, and were followed for at least 6 months after discontinuation. The primary endpoint was the proportion of patients with an increase of at least 2 MHD from the final MHD value within 6 months after discontinuation. We also examined potential associated factors, including age, sex, episodic or chronic migraine, treatment duration ≥6 months, pre-treatment MHD, final MHD
Zitieren
APA
(2026). P028 | WORSENING OF MIGRAINE AFTER DISCONTINUATION OF ANTI-CGRP MONOCLONAL ANTIBODIES: PATIENTS WITHOUT RECURRENCE FOR AT LEAST 6 MONTHS. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15984
Vancouver
P028 | WORSENING OF MIGRAINE AFTER DISCONTINUATION OF ANTI-CGRP MONOCLONAL ANTIBODIES: PATIENTS WITHOUT RECURRENCE FOR AT LEAST 6 MONTHS. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15984
BibTeX
@article{euvimed2026,
title = {P028 | WORSENING OF MIGRAINE AFTER DISCONTINUATION OF ANTI-CGRP MONOCLONAL ANTIBODIES: PATIENTS WITHOUT RECURRENCE FOR AT LEAST 6 MONTHS},
journal = {Confinia Cephalalgica},
year = {2026},
volume = {36},
number = {s1},
doi = {10.4081/cc.2026.15984}
}
EUVIMED